Novocure Stock Current Valuation
| NVCR Stock | USD 19.33 0.15 0.78% |
Valuation analysis of Novocure helps investors to measure Novocure's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 03/23/2025, Enterprise Value is likely to grow to about 4.3 B, though Enterprise Value Over EBITDA is likely to grow to (27.25). Fundamental drivers impacting Novocure's valuation include:
Fairly Valued
Today
Please note that Novocure's price fluctuation is not too volatile at this time. Calculation of the real value of Novocure is based on 3 months time horizon. Increasing Novocure's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novocure stock is determined by what a typical buyer is willing to pay for full or partial control of Novocure. Since Novocure is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novocure Stock. However, Novocure's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 19.33 | Real 18.64 | Target 36.71 | Hype 19.33 | Naive 19.24 |
The intrinsic value of Novocure's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novocure's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novocure helps investors to forecast how Novocure stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novocure more accurately as focusing exclusively on Novocure's fundamentals will not take into account other important factors: Novocure Company Current Valuation Analysis
Novocure's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Novocure Current Valuation | 1.85 B |
Most of Novocure's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novocure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Novocure Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Novocure is extremely important. It helps to project a fair market value of Novocure Stock properly, considering its historical fundamentals such as Current Valuation. Since Novocure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novocure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novocure's interrelated accounts and indicators.
Click cells to compare fundamentals
Novocure Current Valuation Historical Pattern
Today, most investors in Novocure Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Novocure's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Novocure current valuation as a starting point in their analysis.
Novocure Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Novocure has a Current Valuation of 1.85 B. This is 87.13% lower than that of the Health Care Equipment & Supplies sector and 79.79% lower than that of the Health Care industry. The current valuation for all United States stocks is 88.88% higher than that of the company.
Novocure Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novocure's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics of similar companies.Novocure is currently under evaluation in current valuation category among its peers.
Novocure Current Valuation Drivers
We derive many important indicators used in calculating different scores of Novocure from analyzing Novocure's financial statements. These drivers represent accounts that assess Novocure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novocure's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 17.5B | 7.8B | 7.7B | 1.6B | 3.2B | 4.2B | |
| Enterprise Value | 17.7B | 8.1B | 8.1B | 1.9B | 3.1B | 4.3B |
Novocure ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novocure's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novocure's managers, analysts, and investors.Environmental | Governance | Social |
Novocure Fundamentals
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.0877 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 1.85 B | ||||
| Shares Outstanding | 109.92 M | ||||
| Shares Owned By Insiders | 9.70 % | ||||
| Shares Owned By Institutions | 84.85 % | ||||
| Number Of Shares Shorted | 5.2 M | ||||
| Price To Earning | 721.15 X | ||||
| Price To Book | 5.90 X | ||||
| Price To Sales | 3.51 X | ||||
| Revenue | 605.22 M | ||||
| Gross Profit | 469.04 M | ||||
| EBITDA | (109.58 M) | ||||
| Net Income | (168.63 M) | ||||
| Cash And Equivalents | 948.52 M | ||||
| Cash Per Share | 9.06 X | ||||
| Total Debt | 93.13 M | ||||
| Debt To Equity | 1.31 % | ||||
| Current Ratio | 8.08 X | ||||
| Book Value Per Share | 3.32 X | ||||
| Cash Flow From Operations | (26.37 M) | ||||
| Short Ratio | 5.65 X | ||||
| Earnings Per Share | (1.56) X | ||||
| Price To Earnings To Growth | (0.47) X | ||||
| Target Price | 35.57 | ||||
| Number Of Employees | 1.49 K | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 2.12 B | ||||
| Total Asset | 1.24 B | ||||
| Retained Earnings | (1.15 B) | ||||
| Working Capital | 350.2 M | ||||
| Current Asset | 293.9 M | ||||
| Current Liabilities | 28.63 M | ||||
| Net Asset | 1.24 B |
About Novocure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.